{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:30:15Z","timestamp":1793820615427,"version":"4.6.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsurgicalresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Research"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jss.2023.11.067","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T05:12:30Z","timestamp":1703221950000},"page":"705-716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Surgical Resection Alone is Associated With Higher Long-Term Survival Than Multiagent Chemotherapy Alone for Patients With Localized Biliary Tract Cancers"],"prefix":"10.1016","volume":"295","author":[{"given":"Mohamedraed","family":"Elshami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Ammori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Hardacre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Eva","family":"Selfridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bajor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakti","family":"Chakrabarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Mahipal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3341-9521","authenticated-orcid":false,"given":"Lee M.","family":"Ocuin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jss.2023.11.067_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.21037\/cco.2016.10.09","article-title":"Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations","volume":"5","author":"Marcano-Bonilla","year":"2016","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.jss.2023.11.067_bib3","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1245\/s10434-019-07873-z","article-title":"Advances in the diagnosis and treatment of patients with intrahepatic cholangiocarcinoma","volume":"27","author":"Ejaz","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jss.2023.11.067_bib4","doi-asserted-by":"crossref","first-page":"693","DOI":"10.4254\/wjh.v12.i10.693","article-title":"Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma","volume":"12","author":"Akateh","year":"2020","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jss.2023.11.067_bib6","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","article-title":"Swog S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma","volume":"33","author":"Ben-Josef","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2023.11.067_bib7","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jss.2023.11.067_bib8","doi-asserted-by":"crossref","first-page":"942","DOI":"10.21037\/jgo.2017.11.06","article-title":"Current survival and treatment trends for surgically resected intrahepatic cholangiocarcinoma in the United States","volume":"9","author":"Altman","year":"2018","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.jss.2023.11.067_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw202","article-title":"Adjuvant therapy for resected gallbladder cancer: analysis of the national cancer data base","volume":"109","author":"Mantripragada","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jss.2023.11.067_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw324","article-title":"Limited use of adjuvant therapy in patients with resected gallbladder cancer despite a strong association with survival","volume":"109","author":"Mitin","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jss.2023.11.067_bib12","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jss.2023.11.067_bib13","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/SLA.0000000000005641","article-title":"Liver transplantation as a new standard of care in patients with perihilar cholangiocarcinoma? Results from an international benchmark study","volume":"276","author":"Breuer","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.jss.2023.11.067_bib14","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s11605-020-04721-4","article-title":"Liver transplantation for peri-hilar cholangiocarcinoma","volume":"24","author":"Tan","year":"2020","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.jss.2023.11.067_bib15","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s11605-022-05465-z","article-title":"Defining facility volume threshold for optimization of short- and long-term outcomes in patients undergoing resection of perihilar cholangiocarcinoma","volume":"27","author":"Elshami","year":"2022","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.jss.2023.11.067_bib16","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.hpb.2022.07.007","article-title":"Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenocarcinoma","volume":"24","author":"Elshami","year":"2022","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jss.2023.11.067_bib17","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1245\/s10434-019-07657-5","article-title":"Facility type is associated with margin status and overall survival of patients with resected intrahepatic cholangiocarcinoma","volume":"26","author":"Lee","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jss.2023.11.067_bib18","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jamcollsurg.2016.02.012","article-title":"Perihilar cholangiocarcinoma: number of nodes examined and optimal lymph node prognostic scheme","volume":"222","author":"Bagante","year":"2016","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.jss.2023.11.067_bib19","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.hpb.2021.12.007","article-title":"Surgical resection is associated with improved long-term survival of patients with resectable pancreatic head cancer compared to multiagent chemotherapy","volume":"24","author":"Landa","year":"2022","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jss.2023.11.067_bib20","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/01.ede.0000135174.63482.43","article-title":"A structural approach to selection bias","volume":"15","author":"Hernan","year":"2004","journal-title":"Epidemiology"},{"key":"10.1016\/j.jss.2023.11.067_bib21","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.jss.2023.11.067_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/MLR.0b013e31806518ac","article-title":"Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases","volume":"45","author":"Curtis","year":"2007","journal-title":"Med Care"},{"key":"10.1016\/j.jss.2023.11.067_bib23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00001648-199901000-00008","article-title":"Causal diagrams for epidemiologic research","volume":"10","author":"Greenland","year":"1999","journal-title":"Epidemiology"},{"key":"10.1016\/j.jss.2023.11.067_bib24","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/ije\/dyaa213","article-title":"Use of directed acyclic graphs (DAGs) to identify confounders in applied health research: review and recommendations","volume":"50","author":"Tennant","year":"2021","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jss.2023.11.067_bib25","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1245\/s10434-020-08621-4","article-title":"The landmark series: intrahepatic cholangiocarcinoma","volume":"27","author":"Cloyd","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jss.2023.11.067_bib26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13014-018-1024-z","article-title":"Patterns of failure after resection of extrahepatic bile duct cancer: implications for adjuvant radiotherapy indication and treatment volumes","volume":"13","author":"Choi","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.jss.2023.11.067_bib27","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1038\/s41598-019-41622-2","article-title":"Risk factors associated with locoregional failure and estimation of survival after curative resection for patients with distal bile duct cancer","volume":"9","author":"Im","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jss.2023.11.067_bib28","first-page":"73","article-title":"A review of current adjuvant and neoadjuvant systemic treatments for cholangiocarcinoma and gallbladder carcinoma","volume":"7","author":"Allen","year":"2021","journal-title":"Hepatoma Research"},{"key":"10.1016\/j.jss.2023.11.067_bib29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12885-020-6610-4","volume":"20","author":"Goetze","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jss.2023.11.067_bib30","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.ejso.2016.12.008","article-title":"A retrospective analysis of the clinical effects of neoadjuvant combination therapy with full-dose gemcitabine and radiation therapy in patients with biliary tract cancer","volume":"43","author":"Kobayashi","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jss.2023.11.067_bib31","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2022.40.16_suppl.4097","article-title":"NEO-GAP: a phase II single-arm prospective feasibility study of neoadjuvant gemcitabine\/cisplatin\/nab-paclitaxel for resectable high-risk intrahepatic cholangiocarcinoma","volume":"40","author":"Maithel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2023.11.067_bib34","article-title":"Neoadjuvant therapy for cholangiocarcinoma: a comprehensive literature review","volume":"27","author":"Rizzo","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.jss.2023.11.067_bib35","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ejso.2019.03.023","article-title":"Neoadjuvant versus adjuvant chemotherapy for cholangiocarcinoma: a propensity score matched analysis","volume":"45","author":"Yadav","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jss.2023.11.067_bib36","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/jso.27112","article-title":"Neoadjuvant therapy use and association with postoperative outcomes and overall survival in patients with extrahepatic cholangiocarcinoma","volume":"127","author":"Silver","year":"2022","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.jss.2023.11.067_bib37","doi-asserted-by":"crossref","first-page":"555","DOI":"10.21037\/hbsn-20-396","article-title":"Cholangiocarcinoma: a review of the literature and future directions in therapy","volume":"11","author":"Halder","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.jss.2023.11.067_bib38","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata","year":"2018","journal-title":"Br J Surg"},{"key":"10.1016\/j.jss.2023.11.067_bib39","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study","volume":"37","author":"Edeline","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2023.11.067_bib40","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/jjco\/hyy004","article-title":"A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT)","volume":"48","author":"Nakachi","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jss.2023.11.067_bib41","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/s12885-015-1498-0","article-title":"Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial","volume":"15","author":"Stein","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jss.2023.11.067_bib42","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1158\/1078-0432.CCR-21-4462","article-title":"FDA approval summary: ivosidenib for the treatment of patients with advanced unresectable or metastatic, chemotherapy refractory cholangiocarcinoma with an IDH1 mutation","volume":"28","author":"Casak","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jss.2023.11.067_bib43","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/17425255.2022.2039118","article-title":"Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management","volume":"18","author":"Chakrabarti","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jss.2023.11.067_bib44","first-page":"23","article-title":"Pemigatinib: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jss.2023.11.067_bib45","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-021-01567-1","article-title":"Infigratinib: first approval","volume":"81","author":"Kang","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jss.2023.11.067_bib46","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jss.2023.11.067_bib47","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jamcollsurg.2012.12.016","article-title":"Completeness of American cancer registry treatment data: implications for quality of care research","volume":"216","author":"Mallin","year":"2013","journal-title":"J Am Coll Surg"}],"container-title":["Journal of Surgical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002248042300639X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002248042300639X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:11:57Z","timestamp":1793819517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002248042300639X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":42,"alternative-id":["S002248042300639X"],"URL":"https:\/\/doi.org\/10.1016\/j.jss.2023.11.067","relation":{},"ISSN":["0022-4804"],"issn-type":[{"value":"0022-4804","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surgical Resection Alone is Associated With Higher Long-Term Survival Than Multiagent Chemotherapy Alone for Patients With Localized Biliary Tract Cancers","name":"articletitle","label":"Article Title"},{"value":"Journal of Surgical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jss.2023.11.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}